Boehringer Ingelheim appointment to Board Managing Directors
Boehringer Ingelheim announces appointments to Board of Managing Directors
Search
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Living with type 2 diabetes
People living with type 2 diabetes often suffer a degree of stigma. Learn from Jurjen de Lange what it takes to live a good life despite the disease.
Boehringer receives SBTi validation for CO2 reduction targets
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Lameness horses collaboration Sleip app artificial intelligence
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
EASi-HF™ Phase III trial in patients with HFpEF
Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
Boehringer Ingelheim Venture Fund invests precision antimicrobials
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
Phase II results cognitive impairment schizophrenia
Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
Tomorrow's leaders
We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
Combating complex diseases with data
How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Science Stories
Science Stories
Reggie the Red Blood Cell
Join Reggie, our curious red blood cell, on a journey exploring connections between the heart, kidneys and pancreas.
LastMile increases access to veterinary care in Africa
Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
Edda Dankmeyer
Edda Dankmeyer is our Lead of Sustainable Development Communications. She tells us where her passion for sustainability comes from, why she joined us, and how sustainable development can be a key differentiator for the company.
Human Health
Human Health
A lifetime for patients with mental health conditions
Chris Underhill is a social entrepreneur and participant at the Making More Health Convention.
Careers: Winning with people
Our employees are the foundation of our innovative strength. We continue to put people first in everything we do and support our employees in the key moments of their careers.
Horses
Horses
Vaccines
Vaccines